MAPT and Alzheimer disease: In 2022, two multi‐cohort longitudinal studies, including one using PREVENT‐AD data, showed that half of CU individuals identified as being abnormal on both Aβ (A+) and tau (T+) PET biomarkers developed MCI or dementia when followed for a mean of 3.5 years.20, 49